Vaxcyte Q2 net loss $48.5M; VAX-24 Phase 2 fully enrolled with topline data expected Oct/Nov 2022

Vaxcyte, Inc.

2022-Q2 EPS reported -$1.48

Cash, equivalents and investments of $361.4M at June 30, 2022 (vs. $273.1M at Dec. 31, 2021).
R&D expenses $38.5M, up from $17.7M YoY due to VAX-24/VAX-XP/Phase 3 readiness activities.
Net loss $48.5M for Q2 2022 compared to $23.7M in Q2 2021.
Completed enrolment of Phase 2 portion of VAX-24 proof-of-concept study in adults 50-64 (≈800 subjects).
FDA granted Fast Track designation for VAX-24 in adults; topline results expected Oct or Nov 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.